AAV Gene Therapy Vectors

Named corporate participants include Novartis, Pfizer, Sarepta Therapeutics, REGENXBIO and Regeneron Pharmaceuticals Inc. Their work spans AAV9 programs, neuromuscular gene therapies, vector engineering, production and purification. The field also includes specialist developers such as LEXEO Therapeutics Inc. and 4D Molecular Therapeutics, alongside research organizations developing capsids and delivery methods.

Atsena Therapeutics Inc., Shape Therapeutics Inc. and LEXEO Therapeutics Inc. are named startup participants. Atsena works on retinal therapies and dual-vector designs, Shape engineers capsids for targeted delivery, and LEXEO develops AAV-mediated therapies including an AAVrh10-based program. These profiles indicate different development angles; the available facts do not establish a comparative ranking of their prospects.

Viralgen, Andelyn Biosciences and Thermo Fisher Scientific are named manufacturing or supply-side participants. Viralgen has partnered with EpilepsyGTx to advance an AAV therapy and with Apertura Gene Therapy on manufacturing. Andelyn is developing and manufacturing an AAV9-GM2 therapy, while Thermo Fisher supplies bioprocessing tools used in viral-vector manufacturing.

Fudan University, Harvard University and the University of California are prominent research organizations in the available data. Their records include 266, 170 and 185 publications, respectively, in the tracked window. Research topics include retinal delivery, capsid engineering and transduction across target tissues. These counts describe recorded publications, not an independent ranking of research quality.

FACTS records $146.5 million in grants across 124 awards since 2020, plus 54 funding rounds totaling $120.8 billion. The rounds include broad manufacturing investments and other activity not clearly specific to AAV vectors. Treat the round total as a broad recorded figure rather than a reliable estimate of capital invested solely in AAV-vector development.

Regeneron Pharmaceuticals Inc leads the listed patent holders with 68 patents, followed by the University of Massachusetts with 56. The Broad Institute Inc. has 43, Voyager Therapeutics has 42, and Wyvern Pharmaceuticals Inc. has 40. These are patent-holder counts in FACTS and should not be read as a measure of patent quality or commercial value.

No: patent activity declined 51.4% in the last 12 months compared with the previous 12 months, while publication activity grew 18.3%. FACTS also records 2,340 patents within its 24-month window. The contrasting trends suggest that recent technical exploration is more visible in publications than in new patent filings, but the figures alone do not explain the shift.

Recent work includes a September 2026 study of AAVR dependence in retinal transduction from the University of Florida and an August 2026 co-evolutionary AAV2 capsid-engineering study from University College London. In October 2026, EpilepsyGTx and Viralgen announced a partnership to advance AAV gene therapy for epilepsy. Together, these developments address targeting, design and manufacturing.

The main approaches are natural serotypes, engineered capsids, genome architectures, vector production, and purification and analytics. Natural serotypes draw on existing capsid properties; engineering seeks more selective delivery. Genome design adapts the therapeutic cassette, while production and purification work address scale, consistency and product quality. Each approach tackles a different part of the vector’s performance and development challenge.

FACTS identifies neurological disorders, ophthalmic diseases, neuromuscular disorders, liver and metabolic diseases, and cardiovascular diseases as application areas. Neurological disorders have 2,862 recorded documents, while cardiovascular diseases have 1,488. Recent research also addresses retinal delivery, hearing-related cell targeting and lung gene delivery, illustrating the range of tissues under investigation.